ArticleCancer discovery2018
BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 137 citations in OpenAlex.
- Article
- BET inhibitor OPN-2853 in advanced solid tumors and lymphoma: results from the phase 1b PLX124-01 trial.Cancer chemotherapy and pharmacology · 2026Article
- Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107.Molecular oncology · 2026Article
- Epigenetic Targeting in Myeloid Malignancies.Advances in experimental medicine and biology · 2026Review
- Decoding Bromodomain and Extra-Terminal Domain Protein-Mediated Epigenetic Mechanisms in Human Uterine Fibroids.International journal of molecular sciences · 2025Article
- The epigenetic landscape of rheumatoid arthritis: Pathogenesis and drug therapeutic potentials.Acta pharmaceutica Sinica. B · 2025Review
- BRD4 inhibition leads to MDSC apoptosis and enhances checkpoint blockade therapy.The Journal of clinical investigation · 2025Article
- The ETS-family transcription factor PU.1 is a critical regulator of the inhibitory Fcγ receptor IIB expression in humans.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Gut Microbiome Profiling in Eμ-TCL1 Mice Reveals Intestinal Changes and a Dysbiotic Signature Specific to Chronic Lymphocytic Leukemia.Cancer research communications · 2025Article
- BET Protein Inhibition Relieves MDSC-Mediated Immune Suppression in Chronic Lymphocytic Leukemia.Hemato · 2025Article
- Epigenetic Regulation and Therapeutic Targeting of Alternative Splicing Dysregulation in Cancer.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Targeted BET inhibition with OPN-51107 synergizes with venetoclax in chronic lymphocytic leukemia.Leukemia & lymphoma · 2024Article
- Inhibition of bromodomain and extra-terminal proteins targets constitutively active NFκB and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC.Cell communication and signaling : CCS · 2024Article
- Identification of Novel Bromodomain-Containing Protein 4 (BRD4) Binders through 3D Pharmacophore-Based Repositioning Screening Campaign.Molecules (Basel, Switzerland) · 2024Article
- Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.Signal transduction and targeted therapy · 2024Review
- BET inhibition reforms the immune microenvironment and alleviates T cell dysfunction in chronic lymphocytic leukemia.JCI insight · 2024Article
- BiMPADR: A Deep Learning Framework for Predicting Adverse Drug Reactions in New Drugs.Molecules (Basel, Switzerland) · 2024Article
- The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling.Experimental hematology & oncology · 2024Article
- Editorial for theInternational journal of molecular sciences · 2023Article
- Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies.Leukemia & lymphoma · 2023Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
47 authors at 2 institutions in 1 country.
Hatice Gulcin Ozer *Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio.
Dalia El-Gamal *Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio.
Ben Powell *Plexxikon Inc., Berkeley, California.
Zachary A HingDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio.
James S BlachlyDepartment of Biomedical Informatics, The Ohio State University, Columbus, Ohio.
Bonnie HarringtonCollege of Veterinary Medicine, The Ohio State University, Columbus, Ohio.
Shaneice MitchellDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio.
Nicole R GrieselhuberDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio.
Katie WilliamsDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio.
Tzung-Huei LaiDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio.
Lapo AlinariDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio.
Robert A BaiocchiDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio.
Lindsey BrintonDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio.
Elizabeth BaskinDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio.
Matthew CannonDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio.
Larry BeaverDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio.
Virginia M GoettlDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio.
David M LucasDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio.
Jennifer A WoyachDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio.
Deepa SampathDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio.
Amy M LehmanCenter for Biostatistics, The Ohio State University, Columbus, Ohio.
Lianbo YuCenter for Biostatistics, The Ohio State University, Columbus, Ohio.
Jiazhong ZhangPlexxikon Inc., Berkeley, California.
Yan MaPlexxikon Inc., Berkeley, California.
Ying ZhangPlexxikon Inc., Berkeley, California.
Wayne SpevakPlexxikon Inc., Berkeley, California.
Songyuan ShiPlexxikon Inc., Berkeley, California.
Paul SeversonPlexxikon Inc., Berkeley, California.
Rafe ShellooePlexxikon Inc., Berkeley, California.
Heidi CariasPlexxikon Inc., Berkeley, California.
Garson TsangPlexxikon Inc., Berkeley, California.
Ken DongPlexxikon Inc., Berkeley, California.
Todd EwingPlexxikon Inc., Berkeley, California.
Adhirai MarimuthuPlexxikon Inc., Berkeley, California.
Christina TantoyPlexxikon Inc., Berkeley, California.
Jason WaltersPlexxikon Inc., Berkeley, California.
Laura SanftnerPlexxikon Inc., Berkeley, California.
Hamid RezaeiPlexxikon Inc., Berkeley, California.
Marika NespiPlexxikon Inc., Berkeley, California.
Bernice MatusowPlexxikon Inc., Berkeley, California.
Gaston HabetsPlexxikon Inc., Berkeley, California.
Prabha IbrahimPlexxikon Inc., Berkeley, California.
Chao ZhangPlexxikon Inc., Berkeley, California.
Ewy A MathéDepartment of Biomedical Informatics, The Ohio State University, Columbus, Ohio.
Gideon Bollag *Plexxikon Inc., Berkeley, California.
John C Byrd *Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio. rosa.lapalombella@osumc.edu john.byrd@osumc.edu.
Rosa Lapalombella *Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio. rosa.lapalombella@osumc.edu john.byrd@osumc.edu.
The Ohio State University · USMolecular Pathology Laboratory Network (United States) · US
Funding
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3MTargeted Therapy for LeukemiaR35CA197734 · NCI · UNIVERSITY OF CINCINNATI · PI BYRD, JOHN C. · 2015 to 2021
$6.6MTargeted Therapy for Lymphoid MalignanciesR01CA177292 · NCI · OHIO STATE UNIVERSITY · PI ROGERS, KERRY ANNE, WOYACH, JENNIFER A. · 2013 to 2025
$5.3MIntegrative Training in Biomedical SystemsT32GM068412 · NIGMS · OHIO STATE UNIVERSITY · PI PARVIN, JEFFREY D · 2005 to 2020
$2.4MTargeted Therapies for Richters TransformationR01CA214046 · NCI · OHIO STATE UNIVERSITY · PI BAIOCCHI, ROBERT ALAN, BYRD, JOHN C. · 2017 to 2021
$2.3MTargeting BRD4 in Chronic Lymphocytic Leukemia (CLL) Disease Progression to Richter's Transformation (RT)R00CA208017 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ELGAMAL, DALIA · 2018 to 2020
$679kTargeting BRD4 in Chronic Lymphocytic Leukemia (CLL) Disease Progression to Richter's Transformation (RT)K99CA208017 · NCI · OHIO STATE UNIVERSITY · PI ELGAMAL, DALIA · 2016 to 2017
$207kNCI NIH HHS K99 CA208017NCI NIH HHS P30 CA016058NCI NIH HHS R00 CA208017NCI NIH HHS R01 CA177292NCI NIH HHS R01 CA214046NCI NIH HHS R35 CA197734NIGMS NIH HHS T32 GM068412
Abstract
Bromodomain and extra-terminal (BET) family proteins are key regulators of gene expression in cancer. Herein, we utilize BRD4 profiling to identify critical pathways involved in pathogenesis of chronic lymphocytic leukemia (CLL). BRD4 is overexpressed in CLL and is enriched proximal to genes upregulated or
Indexed as
Gene Expression Regulation, LeukemicSignal TransductionAnimalsAntineoplastic AgentsBromodomain Containing ProteinsCell Cycle ProteinsCell Line, TumorCell ProliferationGene Expression ProfilingHumansIsoxazolesLeukemia, Lymphocytic, Chronic, B-CellMiceMice, SCIDNuclear ProteinsPyridinesAntineoplastic AgentsBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsIsoxazolesNuclear ProteinsPyridinesPyrrolesTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.